Richard Vincent is Immusoft’s Chief Financial Officer. He has over 25 years of experience in strategic and operational planning and finance, ranging from private and public offerings in early stage private start-ups to mature large-size international public companies across multiple industries.
He has held senior management positions at Avalyn Pharma (co-founder), Oncternal Therapeutics, Zavante Therapeutics, Meritage Pharma, Sorrento Therapeutics, Elevation Pharmaceuticals, Suneva Medical, Verus Pharmaceuticals, Women First HealthCare, Elan Pharmaceuticals, Phase Metrics, and Deloitte & Touche LLP, where he specialized in emerging growth and publicly reporting companies.
Over the past two decades, Richard’s experience includes raising over $700 million through venture capital, crossover investors, major commercial banks and institutions, and public offering proceeds for high growth pharmaceutical and technology-based companies, and participating in numerable acquisitions, divestitures and license activities valued at over $2.5 billion.
Richard earned his Certified Public Accountant status in California and holds a B.S. degree in business from San Diego State University. He was named 2014 public company CFO of the Year in San Diego by the San Diego Business Journal.